Haemophilus Influenzae (Hib) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)
Conditions: Diphtheria Vaccine Adverse Reaction; Tetanus Vaccine Adverse Reaction; Pertussis Vaccine Adverse Reaction; Haemophilus Influenzae Type B Vaccine Adverse Reaction; Hepatitis B Vaccine Adverse Reaction Interventions: Biological: Recombinant Hepatitis B new Bulk vaccine; Biological: DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine; Biological: Recombinant Hepatitis B vaccine (Registered BioFarma); Biological: Pentabio Sponsors: PT Bio Farma; Hasan Sadikin General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2022 Category: Research Source Type: clinical trials

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b
Conditions: Haemophilus Influenzae Infection; Vaccines Interventions: Biological: Vaccine for the prevention of infections caused by Haemophilus influenza type b; Biological: Placebo Sponsor: St. Petersburg Research Institute of Vaccines and Sera Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2022 Category: Research Source Type: clinical trials